Result of AGM

RNS Number : 3040T

Allergy Therapeutics PLC

23 November 2021

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

Result of Annual General Meeting

23 November 2021 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that, with the exception of resolution 10, which failed to carry, all other resolutions proposed at the 2021 Annual General Meeting ("AGM") were duly passed by shareholders. Voting was conducted by way of a poll.  

Resolutions 1 to 9 (inclusive) were proposed as ordinary resolutions and resolution 10 was proposed as a special resolution. The results of the poll are outlined in the table below.

The Board acknowledges the failure to pass resolution 10 and is disappointed in this outcome. The Board considers the flexibility afforded by these authorities to be in the best interests of the Company and shareholders and notes that this resolution has received support at previous AGMs. However, the Board remains committed to continuing an open and transparent dialogue and will, accordingly, seek to continue to engage with shareholders regarding their views in this area.

Resolution	For:	%age	Against:	%age	Withheld
1.  To receive a copy of the Annual Report for the year ended 30 June 2021	176,577,712	99.99	0	0	0
2. To approve the Directors' Remuneration Report	174,524,577	98.86	1,989,308	1.13	63,827
3. To re-appoint Mary Tavener as a Director	176,161,541	99.98	7,089	0.01	409,082
4. To re-appoint Scott Leinenweber as a Director	173,381,457	98.41	2,787,173	1.58	409,082
5. To re-appoint Tunde Otulana as a Director	176,161,541	99.98	7,089	0.01	409,082
6. To re-appoint Peter Jensen as a Director	173,387,212	98.84	2,022,948	1.15	1,167,552
7. To appoint BDO LLP as auditors of the Company	176,142,079	99.97	32,806	0.02	402,827
8. To authorise the Directors to determine the Auditors remuneration	176,577,712	99.99	0	0	0
9. To authorise the Directors to allot unissued share capital up to a specified amount (s551)	176,565,019	99.98	11,693	0.01	1,000
10 Special Resolution: To disapply pre-emption provisions of s561(1) of the CoAct 2006 up to a specified amount	37,107,171	21.00	139,469,541	78.99	1,000

- ENDS -

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

[phone]

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / David Daley / Davide Salvi

[e-mail]

Stern Investor Relations, Inc.

[phone]

Christina Tartaglia

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved double digit compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .

 

END

 

 

RAGFEEFEDEFSEIF